Irritable Bowel Syndrome Treatment Market Analysis by 2021, 28

The irritable bowel syndrome (IBS) treatment market was valued at US$ 2,153.89 million in 2020 and is projected to reach US$ 4,600.30 million by 2028; it is expected to grow at a CAGR of 10.1% from 2021 to 2028.

The major factors such as the increasing prevalence of irritable bowel syndrome diseases and rising research & development activities drive the market growth. However, the limited number of product availability and treatment inefficiency restrain the market growth. IBS is a common chronic condition that affects the abdominal organ, large intestine. It is also known as spastic colon, mucous colitis, irritable colon, and spastic colitis. The condition is much different than inflammatory bowel disease. It shows symptoms such as cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both at the same. If the symptoms are mild, they can be managed by changing stress, lifestyle, and diet. On the other side, severe symptoms are treated with medication and counseling.

In APAC, many measures have been implemented to contain the spread of novel coronavirus that causes COVID-19. The measures have disrupted the operations of many companies in various industries, including healthcare industry. Staff quarantine, supply-chain failures, and reductions in demand have generated serious complications for companies. Also, there has been a significant drop in in-patient and out-patient care in private hospital chains. To relieve healthcare systems, many clinics are postponing noncritical appointments. This scenario is hindering the growth of the irritable bowel syndrome (IBS) treatment.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Irritable Bowel Syndrome (IBS) Treatment Market: Strategic Insights

Irritable Bowel Syndrome (IBS) Treatment Market

• 
  CAGR (2020 - 2028)

  10.1%
• Market Size 2020
  US$ 2.15 Billion
• Market Size 2028
  US$ 4.6 Billion

Market Dynamics

GROWTH DRIVERS

• XXXXXXX
• XXXXXXX
• XXXXXXX

FUTURE TRENDS

• XXXXXXX
• XXXXXXX
• XXXXXXX

OPPORTUNITIES

• XXXXXXX
• XXXXXXX
• XXXXXXX

Key Players

• Ironwood Pharmaceuticals Inc
• AbbVie
• Sebela Pharmaceuticals Inc
• Takeda Pharmaceutical Company Limited
• Alfasigma S p A
• Astellas Pharma Inc
• AstraZeneca
• Synthetic Biologics Inc
• Bausch Lomb Incorporated

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Type

• IBS with Diarrhea
• IBS with Constipation
• Mixed IBS

Product

• Rifaximin
• Eluxadoline
• Lubiprostone
• Linaclotide

Distribution Channel

• Hospital Pharmacies
• Drug Stores and Retail Pharmacies
• Online Pharmacies

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

 

Market Insights

Increasing Prevalence of Irritable Bowel Syndrome and Associated Conditions

Irritable bowel syndrome is a majorly observed chronic gastrointestinal condition that is caused due to disturbances in bowel habits and abdominal pain. The disease is also known as spastic colon, irritable colon, mucous colitis, and spastic colitis. Irritable bowel syndrome shows symptoms such as abdominal pain, constipation, diarrhea, and cramping. Health systems across the regions are witnessing considerable growth in the incidence of irritable bowel syndrome. A data published by International Foundation for Gastrointestinal Disorders states that among all IBS patients, about 40% patients have mild IBS, around 35% have moderate IBS, and an estimated 25% suffer from severe IBS. Many people don't recognize IBS symptoms.

Certain factors such as food allergies, developing stages of gastroenteritis, sporadic movements of colon, abnormal composition of serotonin in colon, and mild celiac disease are among the risk factors that can cause IBS. These factors are projected to accelerate the rate of IBS prevalence across the world. For instance, according to a study published on NCBI in 2018, IBS is estimated to affect around 10% to 16% of the US population each year. Such staggering prevalence of IBS is likely to boost the irritable bowel syndrome (IBS) treatment market during the forecast period.

Type-Based Insights

Based on type, the Irritable Bowel Syndrome (IBS) Treatment market is segmented into mixed IBS (IBS-M), IBS with diarrhea (IBS-D), and IBS with constipation (IBS-C). In 2020, mixed IBS (IBS-M) segment held the largest share of the market. Also, the same segment is anticipated to register the highest CAGR during the forecast period. The rising prevalence of IBS among women and men are anticipated to propel the demand for the medicines that can treat combined symptoms of constipation and diarrhea. The prevalence of IBS is higher in the aging population. Therefore, the demand for medicines to treat mixed IBS is likely to grow significantly during the forecast period,

Product-Based Insights

Based on product, the irritable bowel syndrome (IBS) treatment market is segmented into rifaximin, eluxadoline, lubiprostone, linaclotide, and others. The linaclotide segment held the largest share of the market in 2020. Also, the same segment is estimated to register the highest CAGR in the market during the forecast period.  The market growth for the segment is attributed to the factors such as the increasing manufacturing of generic version of linaclotide and rising market consolidation for developing and commercializing linaclotide to treat IBS.

Distribution Channel-Based Insights

Based on distribution channel, the irritable bowel syndrome (IBS) treatment market is segmented into hospitals pharmacies, drug stores and retail pharmacies, and online pharmacies. In 2020, the hospitals pharmacies segment held the largest share of the market. However, the drug stores and retail pharmacies segment is expected to register the highest CAGR during the forecast period.

Companies operating in the irritable bowel syndrome (IBS) treatment market adopt the product innovations strategy to meet the evolving customer demands across the world, which also permits them to maintain their brand name in the global market.

Irritable Bowel Syndrome Treatment Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

 

Irritable Bowel Syndrome (IBS) Treatment Market – by Type

• IBS with Diarrhea (IBS-D)
• IBS with Constipation (IBS-C)
• Mixed IBS (IBS-M)

Irritable Bowel Syndrome (IBS) Treatment Market – by Product

• Rifaximin
• Eluxadoline
• Linaclotide
• Lubiprostone
• Others

Irritable Bowel Syndrome (IBS) Treatment Market – by Distribution Channel

• Hospitals Pharmacies
• Drug Stores and Retail Pharmacies
• Online Pharmacies

Irritable Bowel Syndrome (IBS) Treatment Market– by Geography

• North America

  • US
  • Canada
  • Mexico

• Europe

  • France
  • Germany
  • Italy
  • UK
  • Spain
  • Rest of Europe

• Asia Pacific (APAC)

  • China
  • India
  • South Korea
  • Japan
  • Australia
  • Rest of APAC

• Middle East and Africa (MEA)

  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

• South and Central America (SCAM)

  • Brazil
  • Argentina
  • Rest of SCAM

Company Profiles

• Ironwood Pharmaceuticals, Inc.
• AbbVie.
• Sebela Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• Alfasigma S.p.A.
• Astellas Pharma Inc.
• AstraZeneca
• Synthetic Biologics, Inc.
• Bausch + Lomb Incorporated
• Lannett Company Inc